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Human bladder cancer in vitro drug sensitivities: Range and
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Cancer chemotherapy has developed as a result of
clinical trials in patients, selecting the most active
drugs for each type of cancer. This is an empirical
process, because although toxicological and
pharmacokinetic data are available, little or no
information is collected in advance of clinical trial
to predict which histological types of tumour are
likely to benefit. Therefore, there is a strong case
for developing a model system to aid the selection
of drugs most likely to be active against each
tumour type.
Continuous cell lines have been developed from
most human cancers, and it is possible now to
evaluate whether panels of such lines derived from
each histological type of tumour could be used to
select the most active drugs for clinical trial. The
purpose of this study was twofold: firstly, to
measure the in vitro sensitivities of human bladder
cancer cell lines to adriamycin and methotrexate,
two drugs used to treat advanced transitional cell
carcinoma and secondly, to investigate whether the
drug sensitivities expressed by cell lines in vitro are
stable in long-term culture.
The sources of 8 of the 12 cell lines used are
shown in Table I. The remaining 4 lines were
shown to be cross-contaminants of one of the 8
distinct cell lines, T24 (O'Toole et al., 1983). These
cross-contaminated sublines (MGH-U1, MGH-U2,
HU456, HU961T) had been maintained in different
laboratories for periods of up to 10 years, and
consequently provided a means of investigating
whether in vitro drug sensitivities are stable in long-
term culture. Further details concerning the
biological and biochemical characteristics of these
lines are reported elsewhere (Hepburn & Masters,
1983; Trejdosiecwicz et al., 1985).
All cells were grown as monolayers on plastic in
25cm2 flasks (Nunc; Gibco, Paisley, Scotland) and
used over a restricted culture period of 10 passages.
The cells were maintained in RPMI medium
Table I Cell lines used
Cell line Tumour of Previous
designation origin treatment
RTI 12 Bladder primary None
HT1376 Bladder primary None
TCCSUP Bladder primary None
VM-CUB-3 Bladder primary 20Gy pre-surgery
RT4 Bladder recurrence Surgery, 69mC
gold grains
T24 Bladder recurrence Surgery
HT1197 Bladder recurrence Surgery
253J Retroperitoneal Not recorded
lymph-node metastasis
(Gibco) supplemented with 5% heat-inactivated
foetal bovine serum (Flow Laboratories, Irvine,
Scotland), derived from a single batch, at 36.5°C in
a humidified atmosphere of 5% CO2 in air.
Mycoplasma was not demonstrable either in
nutrient agar culture or aceto-orcein stained
monolayers.
Drug sensitivities in vitro were measured using a
clonogenic assay methology, as described previously
(Hepburn et al., 1985). Depending on the popula-
tion doubling time ofthe cell line, between 3,200 and
12,800 cells were plated in each well of a microtest
plate (Nunc 96 well flat base; Gibco) in 0.2ml of
supplemented medium and incubated for 48h under
standard conditions. The medium was then
aspirated and 0.2ml of drug-containing medium
added. Between 7 and 12 drug concentrations were
used, with three replicate wells for each concen-
tration. The control cells received fresh serum-
supplemented medium only, but otherwise were
treated in an identical manner.
Clinical preparations of adriamycin (Farmitalia
Carlo-Erba, Barnet, U.K.) and methotrexate (Lederle
Laboratories, Gosport, U.K.) were dissolved
immediately before use in calcium and magnesium-
free phosphate buffered saline (PBSA) and diluted
at least 100-fold in supplemented medium before
addition to the cells. After a 24h exposure the cells
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were washed using three batches of supplemented
medium, once with PBSA and then detached using
a mixture of 0.1% trypsin (Difco 1:250, London,
England) and 0.003% EDTA (BDH Chemicals
Poole, England) in PBSA. The cells were diluted in
supplemented medium and plated in 5cm plastic
petri dishes (Nunc) containing 5ml of supplemented
medium at cell densities calculated to yield
approximately 100-200 colonies per dish. Plating
efficiency was constant over the range of cell
densities used for all of these lines. The cells were
incubated under standard conditions for 8-21 days,
depending on the growth rate of the cell line. For
incubations of 14 days or longer the medium was
replaced at 7 day intervals. The colonies were fixed
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in methanol (BDH) and stained with 10% Giemsa
(Gurr's improved R66; BDH) and those consisting
of 50 or more cells scored by observation under a
binocular dissecting microscope. The mean colony-
forming ability of drug-treated cells was expressed
as a percentage of that of control cells. A minimum
of three experiments was completed for each drug
and every cell line.
The dose-response curves of the 8 distinct cell
lines following 24h exposure to adriamycin and
methotrexate are shown in Figures 1 and 2,
respectively. In response to adriamycin, all but one
cell line showed an exponential dose-response with
a short initial shoulder region. The exception, 253J,
exhibited a biphasic curve, proving relatively
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Figure 1 The dose-response curves of 8 distinct cell lines to adriamycin are shown. The bars represent the
mean (±1 s.e.) calculated from a minimum of 3 separate experiments, and only errors in excess of 10% of the
mean are included. Each symbol refers to a different cell line: RT112 (A), RT4 ([1), HT1376 (A), HT1197
(O), VM-CUB-3 (*), TCCSUP (-), 253J (O), T24 (O).BLADDER CANCER DRUG SENSITIVITIES IN VITRO 133
(U co
CD
E
0
0
.0
U
l0
100 200 300 400 500 4540
Drug concentration ng ml-1
Figure 2 The dose-response of 8 distinct cell lines to methotrexate are shown. The bars represent the mean
(±1 s.e.) calculated from a minimum of 3 separate experiments, and only errors in excess of 10% are
included. Each symbol refers to a different cell line, corresponding with those in Figure 1: RTI12 (A), RT4
(El), HT1376 (A), HTI197 (0), VM-CUB-3 (*), TCCSUP (0), 253J (U), T24 (O).
resistant at high drug concentrations. With
methotrexate all but one cell line had dose
responses which were initially exponential and then
plateaued at high drug concentrations. The one
exception, HT1376, was extremely resistant and
exhibited a shallow dose-response. The four cross-
contaminated sublines were not included in these
figures, since their dose-response curves were not
significantly different from that of their parent line,
T24.
The concentration of each drug required to
reduce clonogenic cell survival by 70% (ID70) and
the percentage survival at one concentration of each
drug for the 12 cell lines are listed in Table II. The
rank order of sensitivities amongst the cell lines
differed markedly between the two drugs, although
T24 was the most sensitive line to both agents. The
shapes of the dose-response curves were identical to
those previously described for these agents in vitro
(Hill, 1978). This study demonstrates that there is a
broad spectrum of sensitivities amongst bladder cell
lines to methotrexate and a relatively narrow range
of sensitivities to adriamycin.
To validate continuous cell lines for preclinical
drug screening, a comparison should be made
between their in vitro sensitivities and the clinical
response of the tumours of origin to each agent.
Such a comparison is logistically extremely difficult
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Table II The in vitro sensitivities of 12 human bladder cancer cell lines, including T24
and four cross-contaminated sublines (HU456, MGH-Ul, MGH-U2, HU961T) to
adriamycin and methotrexate are listed, showing the drug concentrations required to
reduce clonogenic cell survival by 70% (ID70) and the percentage clonogenic cell survival
following a 24h exporsure to 30ngml1 adriamycin and 100ngml- methotrexate
Adriamycin Methotrexate
Cell line % Survival at % Survival at
designation ID70 (ngml ) 30ngml- ID70 (ngml-1) 00ngml-
HU456 9.0 0.7 11.0 3.5
MGH-U2 9.5 0.9 16.0 6.0
MGH-U1 11.5 1.3 11.0 2.1
T24 12.5 2.0 9.0 2.2
HU961T 13.5 2.6 9.0 4.1
HT1197 14.0 8.3 158.0 34.0
RT112 14.5 6.8 39.0 24.0
HT1376 15.0 7.8 >450.0 95.0
VM-CUB-3 17.0 6.4 >450.0 61.0
TCCSUP 20.0 14.0 22.0 13.0
253J 21.0 16.0 35.0 17.0
RT4 31.5 34.0 95.0 29.0
because cell lines can be derived from only a
minority of bladder tumours, and most patients
with advanced bladder cancer usually receive
combination chemotherapy, not single agents, often
some years after the primary tumour has been
resected. However, there are at least three lines of
indirect evidence indicating that the in vitro
sensitivities of cell lines reflect the clinical response
of the tumours of origin. Firstly, a comparison of
human lung cancer cell lines from untreated
patients and from those who had relapsed following
combination chemotherapy indicated that the
untreated tumours were all more sensitive than the
resistant tumours (Carney et al., 1983). Secondly,
the in vitro sensitivities of human melanoma
xenografts correlated strongly with in vivo response,
except in two cases in which the derived cell lines
also lost the capacity to produce tumours on
transplantation (Tveit et al., 1981). Thirdly, we
have shown that cell lines derived from a tumour
type curable by chemotherapy, testicular germ cell
tumours, are on average five times more sensitive to
adriamycin and cis-platin than bladder cell lines
(Walker et al., 1985). Cumulatively these studies
suggest that, following careful characterization, cell
lines that reflect the drug sensitivities of their
tumour of origin can be selected.
If cell lines are to be used for preclinical drug
screening, it is necessary also that in vitro drug
sensitivities remain relatively stable in long-term
culture. In this study we compared the in vitro
chemosensitivities of T24 and four sublines, which
had been cultured in different laboratories
separately for periods of up to 10 years. All the
lines had similar sensitivities to both methotrexate
and adriamycin, indicating that drug response can
be stable in long-term culture. In support of this
finding no differences in drug sensitivities were
observed between early and permanent cultures
derived from human melanoma xenografts (Tveit et
al., 1981). Similarly, no significant change in 6-
mercaptopurine sensitivity has been observed in the
KB (Hela) cell line over a period of 22 years, based
on data from over 2,000 assays in 13 laboratories
(Shoemaker et al., 1983). In addition, two human
breast cell lines derived from the same biopsy
exhibited similar cell survival curves following
exposure to X-irradation and 12 chemotherapeutic
drugs (Gioanni et al., 1985). However, in contrast
to these data, there are many reports (reviewed by
Heppner, 1984) of heterogeneity in drug sensitivities
between cell lines derived from the same tumour.
Most of these observations have been made on
sublines derived by cloning primary cultures or
established cell lines or following exposure to
chemotherapeutic drugs. Clearly, selection pressures
such as cloning or exposure to chemotherapeutic
drugs will result in sublines with different patterns
of drug sensitivities. In this study, the cell lines
were not cloned, nor had the cells been previously
exposed to chemotherapeutic drugs. Furthermore,
all the cells were grown under identical culture
conditions and used over a restricted culture period
of 10 passages.
While the evidence indicates that cell lines retain
characteristics of their tumours of origin, there
remains the question whether the action of a drug
in vitro is likely to predict the clinical value of thatBLADDER CANCER DRUG SENSITIVITIES IN VITRO 135
agent. It is generally accepted that in vitro data
must be interpreted in conjunction with experi-
mental studies on drug metabolism and pharmaco-
kinetics. For example, drugs that are metabolized in
vivo to yield their cytotoxic derivatives can appear
to be inactive in vitro, and drugs that are detoxified
rapidly in vivo may seem to be highly active in vitro.
Thus, we conclude that cell lines derived from
human bladder tumours may provide a represen-
tative model of this disease and a simple and
economical system for estimating the cytotoxic
activity of drugs in preclinical studies. However,
data are still required to demonstrate that such
findings are ofclinical relevance.
References
CARNEY, D.N., MITCHELL, J.B. & KINSELLA, T.J. (1983).
In vitro radiation and chemotherapy sensitivity of
established cell lines of human small cell lung cancer
and its large morphological variants. Cancer Res., 43,
2806.
GIOANNI, J., COURDI, A., LALANNE, C.M. & 5 others
(1985). Establishment, characterization, chemo-
sensitivity, and radiosensitivity of two different cell
lines derived from a human breast cancer biopsy.
Cancer Res., 45, 1246.
HEPBURN, P.J. & MASTERS, J.R.W. (1983). The biological
characteristics of continuous cell lines derived from
human bladder. In The Pathology of Bladder Cancer,
Bryan, G.T. & Cohen, S.M. (eds) p. 213. CRC Press:
Florida.
HEPBURN, P.J., OLIVER, R.T.D., RILEY, P.A., HILL, B.T. &
MASTERS, J.R.W. (1985). Comparison of the cytotoxic
activities of chemotherapeutic drugs using a human
bladder cancer cell line. Urol. Res., 13, 27.
HEPPNER, G.H. (1984). Tumour heterogeneity. Cancer
Res., 44, 2259.
HILL, B.T. (1978). Cancer chemotherapy: The relevance of
certain concepts of cell cycle kinetics. Biochim.
Biophys. Acta, 516, 389.
O'TOOLE, C.M., POVEY, S., HEPBURN, P. & FRANKS, L.M.
(1983). Identity of some human bladder cancer cell
lines. Nature, 301, 429.
SHOEMAKER, R.H., ABBOTT, B.J., MACDONALD, M.M.,
MAYO, J.G., VENDITTI, J.M. & WOLPERT-DEFILIPPES,
M.K. (1983). Use of the KB cell line for in vitro
cytotoxicity assays. Cancer Treatment Reps., 67, 97.
TREJDOSIEWICZ, L.K., SOUTHGATE, J., DONALD, J.A.,
MASTERS, J.R.W., HEPBURN, P.J. & HODGES, G.M.
(1985). Monoclonal antibodies to human urothelial cell
lines and hybrids: Production and characterization. J.
Urol., 133, 533.
TVEIT, K.M., FODSTAD, 0. & PIHL., A. (1981). The
usefulness of human tumour cell lines in the study of
chemosensitivity. A study of malignant melanomas.
Int. J. Cancer, 28, 403.
WALKER, M.C., MASTERS, J.R.W. & PARRIS, C.N. (1985).
A model system for investigating the factors involved
in tumour cell sensitivity to chemotherapeutic drugs.
Br. J. Cancer, 52, 428.